Resonant Therapeutics

Resonant Therapeutics' platform can simultaneously discover novel targets and high-affinity, functional antibodies at an unprecedented speed. Leveraging new insights into the tumor microenvironment and immune system, their platform can identify targets and therapeutic candidates in any patient-derived tumor tissue or cell line, including cancer stem cells. The platform is scalable to other microenvironment-modulated diseases. They have developed a series of candidate drugs with potent, direct anti-tumor activity, initially focusing on breast and ovarian cancers. Their antibodies are expected to function as standalone therapies or synergistically with emerging immunotherapies.